Elsevier

Journal of Hepatology

Volume 68, Issue 3, March 2018, Pages 563-576
Journal of Hepatology

Review
Clinical states of cirrhosis and competing risks

https://doi.org/10.1016/j.jhep.2017.10.020Get rights and content

Summary

The clinical course of cirrhosis is mostly determined by the progressive increase of portal hypertension, hyperdynamic circulation, bacterial translocation and activation of systemic inflammation. Different disease states, encompassing compensated and decompensated cirrhosis and a late decompensated state, are related to the progression of these mechanisms and may be recognised by haemodynamic or clinical characteristics. While these disease states do not follow a predictable sequence, they correspond to varying mortality risk. Acute-on-chronic liver failure may occur either in decompensated or in compensated cirrhosis and is always associated with a high short-term mortality. The increasing severity of these disease states prompted the concept of clinical states of cirrhosis. A multistate approach has been considered to describe the clinical course of the disease. Such an approach requires the assessment of the probabilities of different outcomes in each state, which compete with each other to occur first and mark the transition towards a different state. This requires the use of competing risks analysis, since the traditional Kaplan-Meier analysis should only be used in two-state settings. Accounting for competing risks also has implications for prognosis and treatment efficacy research. The aim of this review is to summarise relevant clinical states and to show examples of competing risks analysis in multistate models of cirrhosis.

Introduction

Cirrhosis is typically classified as compensated or decompensated, based on the absence or presence (or previous history) of variceal bleeding, ascites, jaundice or encephalopathy.[1], [2], [3] The significantly longer survival, usually symptomless, and better quality of life experienced by patients with compensated cirrhosis compared to those with decompensated cirrhosis, has brought about the concept that compensated and decompensated cirrhosis are distinct clinical states of the disease.[4], [5] Further disease states have been identified according to the presence of oesophageal varices and to the presence of only one or more disease complications.[4], [6], [7], [8], [9], [10]

Development of gastro-oesophageal varices and decompensation usually do not occur below the portal pressure threshold of clinically significant portal hypertension (CSPH) defined by hepatic venous pressure gradient (HVPG) ≥10 mmHg.[11], [12], [13] Increasing portal pressure, bacterial translocation, inflammation and hyperdynamic circulation are likely mechanisms of decompensation,14 which progresses to a late decompensation state characterised by further worsening of liver function associated with other organ dysfunction, while acute-on-chronic liver failure (ACLF) may occur in any disease state. Histological stages15 of cirrhosis also parallel the progression of portal hypertension[16], [17] and clinical states of the disease.[18], [19]

This body of evidence supports a multistate approach to the clinical course of cirrhosis, which implies a specific statistical methodology, since the Kaplan-Meier (KM) survival curves[20], [21] may not capture clinical state transitions following the occurrence of a competing event, before the event of interest. For example, decompensation before death is not captured by a survival curve of compensated cirrhosis. In this situation, the cumulative incidence function (CIF), based on the Aalen-Johansen estimator allows a more realistic description of the disease course, by providing the incidence of the competing events.[22], [23], [24]

The clinical course of cirrhosis encompasses several disease states which require multistate models and competing risks analysis for proper assessment.

Herein, the clinical course, competing risks and clinical states of cirrhosis will be reviewed and examples of possible multistate models of the disease will be provided.

Section snippets

The clinical course of cirrhosis

Cirrhosis may result from chronic liver inflammation from any cause, following parenchymal necrosis, activated fibrogenesis, angiogenesis and profound vascular changes. Increased hepatic resistance to blood flow, derived from both mechanical obstacle and vasoconstriction resulting from endothelial dysfunction and hepatic stellate cells contraction, gradually leads to portal hypertension. The ensuing adaptive splanchnic vasodilation further contributes to aggravate portal hypertension and

Clinical states in cirrhosis

Several clinical conditions associated with significantly different outcomes have been proposed as relevant clinical states during the course of the disease[4], [5], [8], [10], [14], [106], [107] (Fig. 1). However, it is notable that there is no predictable sequence of such clinical states and that they may not be considered as progressive disease stages. However, clinical states enable the classification of patients according to increasing mortality risk. Moreover, assessing transitions across

Management implications of clinical states of cirrhosis

Recognising different clinical states may have important implications on the most likely clinical outcomes. Hence, clinical states may be used to inform treatment interventions to prevent disease progression. In fact, there is evidence that in compensated patients without varices (state 1) the most appropriate approach is aetiological treatment, particularly in those with MPH (state 0) in whom NSBBs do not appreciably reduce portal hypertension.[13], [97] In these patients, non-invasive

Competing risks in cirrhosis

A competing risk is the risk of an event whose occurrence either precludes the occurrence of another event or modifies the probability that it will occur. Along the clinical course of cirrhosis, many clinical conditions, or states, may be characterised by competing outcomes which require competing risks analysis to correctly assess the relevant risks. Several such conditions are shown (Table 1), where examples of outcomes of interest are reported together with potentially relevant competing

Competing risks analysis

Recognising competing risks is important because, in the presence of competing risks, the KM estimator21 invariably results in upward biased estimates.[22], [23], [24], [135] Competing risks analysis is based on the CIF which, by using the Aalen-Johansen estimator,23 partitions the probability of any event into the probabilities that each event occurs first, resulting in an overall event probability (or the sum of the probabilities of each event) correctly ranging from zero to one. The

Building multistate models in cirrhosis

Clinical states should be conceived as a flexible concept and specific clinical states should be defined whenever a specific prognostic question makes it appropriate (Table 1). As an example, in the same study of the clinical course of cirrhosis referred to earlier,10 the 20-year cumulative probability of death (1-KM) was 0.62, in 377 patients with compensated cirrhosis, and 0.93 after decompensation in 224 patients who developed decompensation during the follow-up (Fig. 4A). However, in

Competing risks and clinical research

As shown in previous sections in this article, the most obvious field of application for competing risks analysis is the study of the clinical course of diseases in every situation where relevant competing risks are identified.

A second relevant field where competing risks should be appropriately accounted for is prognosis research. A major aim of this type of research is to find accurate predictors of a disease outcome in a given time. The hypothesis underlying this research is that one or more

Conclusions

The clinical spectrum of cirrhosis encompasses several clinical states, from a very early state of compensated cirrhosis with subclinical portal hypertension, to the late decompensation state with extreme hyperdynamic circulation, bacterial translocation and inflammation. The progression across such states does not occur through a predictable sequence, because of the variable interplay between pathophysiological mechanisms. Therefore, a multistate approach provides a more realistic description

Financial support

P. Rebora was supported by the grant of the Italian Minister of Education, University and Research (MIUR) – Italy SIR 2014 (RBSI14LOVD).

Conflict of interest

The authors declare no conflicts of interest that pertain to this work.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors’ contribution

Gennaro D’Amico: review concepts and project, data collection, elaboration of examples, text and figures. Alberto Morabito: statistical concepts and data analysis for examples. Mario D’Amico: data collection; cohort study for the examples included in the review; text revision. Linda Pasta: responsible for the cohort study used for the examples included in the review. Giuseppe Malizia: review project and text revision. Paola Rebora: statistical concepts, examples and text revision. Maria Grazia

References (144)

  • D.Y. Graham et al.

    The course of patients after variceal hemorrhage

    Gastroenterology

    (1981)
  • B. Bernard et al.

    Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis

    Hepatology

    (1997)
  • F. Salerno et al.

    Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data

    Gastroenterology

    (2007)
  • C. Bureau et al.

    Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites

    Gastroenterology

    (2017)
  • S. Piano et al.

    Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites

    J Hepatol

    (2013)
  • C. Fagundes et al.

    A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis

    J Hepatol

    (2013)
  • P. Angeli et al.

    Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites

    J Hepatol

    (2015)
  • G. Fede et al.

    Renal Failure and cirrhosis: a Systematic review of mortality and prognosis

    J Hepatol

    (2012)
  • F. Salerno et al.

    Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice

    J Hepatol

    (2011)
  • R. Wiest et al.

    Pathological bacterial translocation in liver cirrhosis

    J Hepatol

    (2014)
  • M. Borzio et al.

    Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study

    Dig Liver Dis

    (2001)
  • J. Fernandez et al.

    Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis

    Hepatology

    (2002)
  • R. Jalan et al.

    Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013

    J Hepatol

    (2014)
  • A.S. Lok et al.

    Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease

    Gastroenterology

    (2009)
  • E.G. Giannini et al.

    Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma

    Clin Gastro Hepatol

    (2006)
  • C. Ripoll et al.

    Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis

    J Hepatol

    (2009)
  • P.H. Liu et al.

    Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems

    J Hepatol

    (2016)
  • A. Albillos et al.

    Cirrhosis associated imuune dysfunction: distinctive features and clinical relevance

    J Hepatol

    (2014)
  • P. Kubes et al.

    Sterile inflammation in the liver

    Gastroenterology

    (2012)
  • R. Jalan et al.

    Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure

    J Hepatol

    (2014)
  • R. Jalan et al.

    The CLIF consortium acute decompensation score (CLIF-C Ads) for prognosis of hospitalized cirrhotic patients without acute-on-cronich liver failure

    J Hepatol

    (2015)
  • S. Piano et al.

    Incidence, predictors and outcome of acute-on-chronic liver failure in outpatients with cirrhosis

    J Hepatol

    (2017)
  • P. Bedossa et al.

    Cirrhosis regression and subclassification

    Pathology

    (2013)
  • J. Vorobioff et al.

    Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study

    Gastroenterology

    (1996)
  • M. Mandorfer et al.

    Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension

    J Hepatol

    (2016)
  • A. Van der Meer et al.

    Risk of cirrhosis related complications in patients with advanced fibrosis following hepatitis c virus eradication

    J Hepatol

    (2017)
  • S. Bruno et al.

    Survival of patients with HCV cirrhosis and sustained virological response is similar to the general population

    J Hepatol

    (2016)
  • M. Reig et al.

    Unexpected high rate of early tumor recurrence in patients with HCV related HCC undergoing interferon free therapy

    J Hepatol

    (2016)
  • J.B. Saunders et al.

    A 20-year prospective study of cirrhosis

    Brit Med J

    (1981)
  • P. Ginés et al.

    Compensated cirrhosis. Natural history and prognostic factors

    Hepatology

    (1987)
  • G. Garcia-Tsao et al.

    Now there are many stages where before there was one: in search of pathophysiological classification of cirrhosis

    Hepatology

    (2010)
  • S. Bruno et al.

    Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long term prospective study

    Am J Gastroenterol

    (2009)
  • E. Vilar Gomez et al.

    The matural history of compensated HCV-related cirrhosis: a prospective long-term study

    J Hepatol

    (2013)
  • P. Jepsen et al.

    The clinical course of alcoholic liver cirrhosis: A Danish population-based cohort study

    Hepatology

    (2010)
  • A. Zipprich et al.

    Prognostic indicators of survival in patients with compensated and decompensated cirrhosis

    Liv Int

    (2012)
  • G. D’Amico et al.

    Competing risks and prognostic stages in cirrhosis: a 25-year inception cohort study of 494 patients

    Aliment Pharmacol Ther

    (2014)
  • R.J. Groszmann et al.

    Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis

    N Engl J Med

    (2005)
  • C. Villanueva et al.

    Development of hyperdinamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension

    Hepatology

    (2016)
  • R.G.N. Kutami et al.

    The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with wedged hepatic vein pressure and clinical features

    Hepatology

    (2000)
  • S. Sethasine et al.

    Quantitative histological-hemodynamic correlations in cirrhosis

    Hepatology

    (2012)
  • Cited by (300)

    • The Story of Ammonia in Liver Disease: An Unraveling Continuum

      2024, Journal of Clinical and Experimental Hepatology
    View all citing articles on Scopus
    View full text